Mitochondrial tRNA(Leu(UUR)) mutation m.3302A > G presenting as childhood-onset severe myopathy: threshold determination through segregation study.
Mitochondrial tRNA(Leu(UUR)) mutation m.3302A > G is associated with respiratory chain complex I deficiency and has been described as a rare cause of mostly adult-onset slowly progressive myopathy. Five families with 11 patients have been described so far; 5 of them died young due to cardiorespiratory failure. Here, we report on a segregation study in a family with an index patient who already presented at the age of 18 months with proximal muscular hypotonia, abnormal fatigability, and lactic acidosis. This early-onset myopathy was rapidly progressive. At 8 years, the patient is wheel-chair bound, requires nocturnal assisted ventilation, and suffers from recurrent respiratory infections. Severe complex I deficiency and nearly homoplasmy for m.3302A > G were found in muscle. We collected blood, hair, buccal swabs and muscle biopsies from asymptomatic adults in this pedigree and determined heteroplasmy levels in these tissues as well as OXPHOS activities in muscle. All participating asymptomatic adults had normal OXPHOS activities. In contrast to earlier reports, we found surprisingly little variation of heteroplasmy levels in different tissues of the same individual. Up to 45% mutation load in muscle and up to 38% mutation load in other tissues were found in non-affected adults. The phenotypic spectrum of tRNA(Leu(UUR)) m.3302A > G mutation seems to be wider than previously described. A threshold of more than 45% heteroplasmy in muscle seems to be necessary to alter complex I activity leading to clinical manifestation. The presented data may be helpful for prognostic considerations and counseling in affected families.
Ballhausen
Diana
D
Division of Molecular Pediatrics, Centre Hospitalier Universitaire Vaudois, CI 02-35, Av P Decker 2, 1011 Lausanne, Switzerland. diana.ballhausen@chuv.ch
Guerry
Frédéric
F
Hahn
Dagmar
D
Schaller
André
A
Nuoffer
Jean-Marc
JM
Bonafé
Luisa
L
Jeannet
Pierre-Yves
PY
Jacquemont
Sebastien
S
D017668:Age of Onset; D001706:Biopsy; D002478:Cells, Cultured; D002648:Child; D004252:DNA Mutational Analysis; D018450:Disease Progression; D004734:Energy Metabolism; D005260:Female; D020022:Genetic Predisposition to Disease; D006801:Humans; D008297:Male; D017240:Mitochondrial Myopathies / Q000150:complications / Q000175:diagnosis / Q000201:enzymology / Q000235:genetics* / Q000503:physiopathology / Q000628:therapy; D018908:Muscle Weakness / Q000201:enzymology / Q000235:genetics; D009154:Mutation; D010085:Oxidative Phosphorylation; D010375:Pedigree; D010641:Phenotype; D052097:Quadriceps Muscle / Q000201:enzymology / Q000503:physiopathology; D012313:RNA / Q000235:genetics*; D000077278:RNA, Mitochondrial; D012343:RNA, Transfer / Q000235:genetics*; D012720:Severity of Illness Index
D000077278:RNA, Mitochondrial; D012313:RNA; D012343:RNA, Transfer
Arch Neurol. 2005 Dec;62(12):1920-3
16344351
J Clin Invest. 1990 Jan;85(1):177-84
2153151
Nucleic Acids Res. 2006;34(22):6404-15
17130166
Biol Chem. 2001 Aug;382(8):1147-56
11592395
Clin Chim Acta. 1984 Jun 27;140(1):39-46
6430598
Nat Genet. 1999 Oct;23(2):147
10508508
Neuromuscul Disord. 2004 Oct;14(10):683-8
15351426
J Biol Chem. 1993 Sep 15;268(26):19559-64
8366098
Neuromuscul Disord. 2000 Aug;10(6):460-2
10899455
J Mol Biol. 2004 Mar 26;337(3):535-44
15019775
Curr Opin Neurol. 2007 Oct;20(5):564-71
17885446
Methods Cell Biol. 2001;65:97-117
11381612
Biochim Biophys Acta. 2003 Sep 23;1642(1-2):115-23
12972300
Biochem J. 1969 Sep;114(3):597-610
5820645
Clin Chim Acta. 1994 Jul;228(1):35-51
7955428
BMJ. 2009 Jan 30;338:b94
19181733